ISPC vs PATH
iSpecimen Inc (ISPC) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
iSpecimen Inc (ISPC) is a diagnostics & research company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ISPC revenue for 2024-12-31 was $9.3M. Net income was -$12.5M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ISPC currently screens at market cap $4.4M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ISPC currently screens at market cap $4.4M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ISPC and PATH stock pages for the full models.
Not investment advice.